Heat Biologics Stock Forecast, Price & News

Heat Biologics (NASDAQ:HTBX) Frequently Asked Questions

Is Heat Biologics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Heat Biologics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Heat Biologics stock.
View analyst ratings for Heat Biologics or view top-rated stocks.

What stocks does MarketBeat like better than Heat Biologics?

Wall Street analysts have given Heat Biologics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Heat Biologics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Heat Biologics' next earnings date?

Heat Biologics is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Heat Biologics.

How were Heat Biologics' earnings last quarter?

Heat Biologics, Inc. (NASDAQ:HTBX) announced its earnings results on Tuesday, August, 10th. The biopharmaceutical company reported ($0.26) EPS for the quarter, topping the Zacks' consensus estimate of ($0.31) by $0.05. Heat Biologics had a negative net margin of 1,198.17% and a negative trailing twelve-month return on equity of 23.43%.
View Heat Biologics' earnings history.

How has Heat Biologics' stock been impacted by COVID-19?

Heat Biologics' stock was trading at $0.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, HTBX stock has increased by 791.4% and is now trading at $6.24.
View which stocks have been most impacted by COVID-19.

When did Heat Biologics' stock split? How did Heat Biologics' stock split work?

Heat Biologics shares reverse split before market open on Monday, January 22nd 2018. The 1-10 reverse split was announced on Friday, January 19th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 19th 2018. An investor that had 100 shares of Heat Biologics stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for HTBX?

4 analysts have issued twelve-month target prices for Heat Biologics' stock. Their forecasts range from $14.00 to $22.00. On average, they expect Heat Biologics' share price to reach $19.00 in the next year. This suggests a possible upside of 204.5% from the stock's current price.
View analysts' price targets for Heat Biologics or view top-rated stocks among Wall Street analysts.

Who are Heat Biologics' key executives?

Heat Biologics' management team includes the following people:

• Mr. Jeffrey Alan Wolf, Founder, Chairman, CEO & Pres (Age 58, Pay $1.16M)
• Mr. William L. Ostrander, CFO & Sec. (Age 53, Pay $271.92k)
• Dr. Justin Stebbing M.D., M.A., FRCP, FRCPath, Ph.D., Chief Medical Advisor and Member of Scientific & Clinical Advisory Board
• Colonel George E. Peoples Jr., F.A.C.S., M.D., FACS, Chief Medical Advisor
• Dr. Anthony M. Manning, Chief Scientific Advisor (Age 59)

Who are some of Heat Biologics' key competitors?

Some companies that are related to Heat Biologics include Pharming Group (PHAR), Albireo Pharma (ALBO), Imago BioSciences (IMGO), Spero Therapeutics (SPRO), Adagene (ADAG), BeyondSpring (BYSI), Mirum Pharmaceuticals (MIRM), Landos Biopharma (LABP), DiaMedica Therapeutics (DMCAF), Altimmune (ALT), Nabriva Therapeutics (NBRV), Radius Health (RDUS), Chimerix (CMRX), Pharvaris (PHVS) and Calliditas Therapeutics AB (publ) (CALT).
View all of HTBX's competitors.

What other stocks do shareholders of Heat Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heat Biologics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Vaxart (VXRT), Bionano Genomics (BNGO), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), ADMA Biologics (ADMA), Novan (NOVN) and VBI Vaccines (VBIV).

What is Heat Biologics' stock symbol?

Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX."

Who are Heat Biologics' major shareholders?

Heat Biologics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.41%), BlackRock Inc. (1.89%), Geode Capital Management LLC (0.86%), Principal Financial Group Inc. (0.52%), State Street Corp (0.39%) and Morgan Stanley (0.26%). Company insiders that own Heat Biologics stock include Edward B Smith III and John K A Prendergast.
View institutional ownership trends for Heat Biologics.

Which institutional investors are selling Heat Biologics stock?

HTBX stock was sold by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., Price T Rowe Associates Inc. MD, Sigma Planning Corp, Susquehanna Fundamental Investments LLC, BlackRock Inc., IndexIQ Advisors LLC, Group One Trading L.P., and Simplex Trading LLC. Company insiders that have sold Heat Biologics company stock in the last year include Edward B Smith III, and John K A Prendergast.
View insider buying and selling activity for Heat Biologics or view top insider-selling stocks.

Which institutional investors are buying Heat Biologics stock?

HTBX stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., State Street Corp, Morgan Stanley, Morgan Stanley, Citadel Advisors LLC, Geode Capital Management LLC, Squarepoint Ops LLC, and Virtu Financial LLC.
View insider buying and selling activity for Heat Biologics or or view top insider-buying stocks.

How do I buy shares of Heat Biologics?

Shares of HTBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Heat Biologics' stock price today?

One share of HTBX stock can currently be purchased for approximately $6.24.

How much money does Heat Biologics make?

Heat Biologics has a market capitalization of $158.48 million and generates $2.95 million in revenue each year.

How many employees does Heat Biologics have?

Heat Biologics employs 39 workers across the globe.

What is Heat Biologics' official website?

The official website for Heat Biologics is www.heatbio.com.

Where are Heat Biologics' headquarters?

Heat Biologics is headquartered at 627 DAVIS DRIVE SUITE 400, MORRISVILLE NC, 27560.

How can I contact Heat Biologics?

Heat Biologics' mailing address is 627 DAVIS DRIVE SUITE 400, MORRISVILLE NC, 27560. The biopharmaceutical company can be reached via phone at 919-240-7133 or via email at [email protected].